Skip to main content
Back to feed
HealthReportedLow
2.1

FDA Approves Egetis' Emcitate for MCT8 Deficiency Thyrotoxicosis

FDA approved Egetis Therapeutics' Emcitate (tiratricol) for peripheral thyrotoxicosis in MCT8 deficiency, a rare genetic disorder. This is a regulatory milestone for the company, but market impact is limited to niche orphan drug segment.

Dagens Industri4 days agoUS, SECredibility 27%View source

Score Breakdown

Mosaic Score2.1
Model confidence0.9
Significance0.1
Source credibility0.3

Intelligence Tags

#fda#orphan-drug#rare-disease#pharmaceutical#regulatory-approval

Entities

countrycountry
Source

Related signals

8 found